XML 50 R38.htm IDEA: XBRL DOCUMENT
v3.22.1

Research Collaboration and License Agreement (Details) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Dec. 31, 2014 USD ($) payment
Research Collaboration and License Agreement |  |  |
Research and development | $ 36,318,000 | $ 24,245,000 |
Research Collaboration and License Agreement | Zealand Pharma |  |  |
Research Collaboration and License Agreement |  |  |
Aggregate milestone payment |  |  | $ 1,000,000.0
Number of development milestone payments | payment |  |  | 3
Research and development | $ 0 | $ 0 |

X
- Definition The aggregate amount of milestone payment made by the entity. + References No definition available. + Details
Name: | ptgx_AggregateAmountOfMilestonePayment
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of development milestone payments in collaboration agreement. + References No definition available. + Details
Name: | ptgx_NumberOfDevelopmentMilestonePayments
Namespace Prefix: | ptgx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |